Spyre Therapeutics Is Maintained at Buy by Guggenheim
Spyre Therapeutics Analyst Ratings
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
Baird Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
Spyre Therapeutics Advances SPY003 for IBD Treatment
Paragon Therapeutics Granted Spyre Therapeutics An Exclusive License To Develop, Manufacture, And Commercialize Certain Antibodies And Products Targeting IL-23 For Irritable Bowel Disease, Paragon Will Receive $22M As Milestone Payments And Further...
Promising Advancements in Spyre Therapeutics' Programs Drive Buy Rating
Wells Fargo Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40
Wells Fargo Issues a Buy Rating on Spyre Therapeutics (SYRE)
Express News | Spyre Therapeutics Inc : Jefferies Raises Target Price to $37 From $31
Express News | Spyre Therapeutics Inc: Spy003 First-in-Human Dosing Now Expected Q1 2025
Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW Supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations
Spyre Therapeutics Announces Grants of Inducement Awards
Express News | Spyre Therapeutics Appoints DR. Sheldon Sloan as Chief Medical Officer
Press Release: Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40
Spyre Therapeutics Poised for Market Leadership With Promising IBD Drug Candidates
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
LifeSci Capital analyst Sam Slutsky maintains $Spyre Therapeutics(SYRE.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 47.5%
Spyre Therapeutics to Participate in Upcoming Investor Conference
Spyre Therapeutics Files for $500M Mixed Securities Shelf